MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
dc.contributor.author | Umerez, Maitane | |
dc.contributor.author | Gutiérrez Camino, Ángela | |
dc.contributor.author | Muñoz Maldonado, Carmen | |
dc.contributor.author | Martín Guerrero, Idoia | |
dc.contributor.author | García-Orad Carles, África | |
dc.date.accessioned | 2017-05-11T07:57:46Z | |
dc.date.available | 2017-05-11T07:57:46Z | |
dc.date.issued | 2017-03-27 | |
dc.identifier.citation | Pharmacogenomics & Personalized Medicine 10 : 69-78 (2017) | es_ES |
dc.identifier.issn | 1178-7066 | |
dc.identifier.uri | http://hdl.handle.net/10810/21505 | |
dc.description.abstract | Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia ( ALL). Methylenetetrahydrofolate reductase ( MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of published reports do not find association or present opposite effect. Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter genes or microRNA-related genes. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Dove Medical Press | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.subject | MTHFR | es_ES |
dc.subject | toxicity | es_ES |
dc.subject | outcome | es_ES |
dc.subject | C677T | es_ES |
dc.subject | A1298C | es_ES |
dc.subject | methylenetetrahidrofolate reductase C677T | es_ES |
dc.subject | genetic polymorphisms | es_ES |
dc.subject | candidate genes | es_ES |
dc.subject | risk-factors | es_ES |
dc.subject | children | es_ES |
dc.subject | toxicity | es_ES |
dc.subject | pharmacogenetics | es_ES |
dc.subject | association | es_ES |
dc.subject | SLCO1B1 | es_ES |
dc.subject | metaanalysis | es_ES |
dc.title | MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2017 Umerez et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php | es_ES |
dc.rights.holder | Atribución-NoComercial 3.0 España | * |
dc.relation.publisherversion | https://www.dovepress.com/mthfr-polymorphisms-in-childhood-acute-lymphoblastic-leukemia-influenc-peer-reviewed-article-PGPM | es_ES |
dc.identifier.doi | 10.2147/PGPM.S107047 | |
dc.departamentoes | Genética, antropología física y fisiología animal | es_ES |
dc.departamentoeu | Genetika,antropologia fisikoa eta animalien fisiologia | es_ES |
dc.subject.categoria | MOLECULAR MEDICINE | |
dc.subject.categoria | PHARMACOLOGY AND PHARMACY |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2017 Umerez et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php